News

Prof Wang was invited to attend Tigermed's ASCO Pre-Event Webinar as a Speaker to introduce Qurgen’s breakthrough cell converting cancer therapy and recent progress in its Phase I clinical trial.

no infusion related reaction (IRR) has occurred during the 48-hour continuous infusion by pump, this indicates a significantly enhanced safety of SON-DP treatment.

Qurgen has completed SON-DP treatment for multiple late-stage solid tumor patients for over 18-months at low dose levels (2-4.5 mg/kg) and observed continue tumor shrinkage after 18-month SON-DP treatment without teratoma

Qurgen expanded 4 additional hospitals (Sarah Cannon Research Institute Tennessee, HCA HealthONE Denver, California Research Institute, LLC, Allison, Curtis, Kingsley, Meoz, Michael & Sanchez, Prof. Corp., DBA Comprehensive Cancer Centers of Nevada).

Qurgen is happy to announce that the blood and biopsy tissue results of a late-stage of ocular melanoma patient indicated complete melanoma driver gene mutations repairment under a 9-month

Suzhou Fuent expanded 5 additional clinical hospitals in China (Shandong Cancer Hospital, The First Hospital of Lanzhou University, Beijing Go Broad Hospital, Sun Yat-sen University Cancer Center, The First Affiliated Hospital of Xi’an Jiaotong University).

Qurgen Inc. was named one of the World's Top 10 Innovative Companies by MedHealth magazine. MedHealth stated: "Qurgen is more than a biotechnology company; it is a catalyst for the transformation of modern medicine. By developing therapies that turn the impossible into reality, Qurgen has set new standards and concepts in cancer treatment, regenerative medicine, and longevity research. With its commitment to scientific excellence, intellectual property strength, and in-house manufacturing capabilities, Qurgen is poised to become a global leader in the next generation of oncology therapeutics."

 The number of Phase I clinical centers in China has expanded to 10, with an additional 5 Class III Grade A hospitals.